123,315 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 123,315 shares of the company's stock, valued at approximately $5,394,000. ExodusPoint Capital Management LP owned about 0.07% of Revolution Medicines as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Captrust Financial Advisors increased its position in Revolution Medicines by 4.1% in the third quarter. Captrust Financial Advisors now owns 8,459 shares of the company's stock worth $384,000 after buying an additional 337 shares during the last quarter. Verition Fund Management LLC purchased a new stake in Revolution Medicines in the 3rd quarter worth about $645,000. Point72 DIFC Ltd bought a new stake in Revolution Medicines in the 3rd quarter valued at about $422,000. Quarry LP bought a new stake in Revolution Medicines in the 3rd quarter valued at about $82,000. Finally, State Street Corp increased its stake in shares of Revolution Medicines by 4.1% in the third quarter. State Street Corp now owns 5,279,584 shares of the company's stock worth $239,429,000 after purchasing an additional 208,516 shares in the last quarter. Institutional investors own 94.34% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on RVMD shares. HC Wainwright boosted their price objective on Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Stifel Nicolaus reduced their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. UBS Group boosted their target price on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Needham & Company LLC restated a "buy" rating and set a $59.00 price target on shares of Revolution Medicines in a research report on Tuesday. Finally, Wedbush reiterated an "outperform" rating and issued a $67.00 price objective on shares of Revolution Medicines in a report on Thursday, February 27th. Twelve research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Revolution Medicines currently has an average rating of "Buy" and a consensus target price of $65.23.

Remove Ads

Insider Activity at Revolution Medicines

In other news, COO Margaret A. Horn sold 3,058 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the transaction, the chief operating officer now owns 153,533 shares of the company's stock, valued at $5,993,928.32. This trade represents a 1.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark A. Goldsmith sold 11,738 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $458,251.52. Following the transaction, the insider now owns 441,564 shares of the company's stock, valued at approximately $17,238,658.56. This trade represents a 2.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is owned by company insiders.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD traded down $2.48 during trading on Thursday, reaching $32.64. 661,570 shares of the stock traded hands, compared to its average volume of 1,432,295. The stock has a market cap of $6.07 billion, a P/E ratio of -9.09 and a beta of 1.37. The stock has a 50-day moving average of $38.71 and a two-hundred day moving average of $44.84. Revolution Medicines, Inc. has a 52-week low of $29.17 and a 52-week high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.11). Sell-side analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.